Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
CLASP II TR
A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Effectiveness of Transcatheter Tricuspid Valve Repair With the Edwards PASCAL Transcatheter Valve Repair System and Optimal Medical Therapy (OMT) Compared to OMT Alone in Patients With Tricuspid Regurgitation
1 other identifier
interventional
870
2 countries
79
Brief Summary
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Dec 2019
Longer than P75 for not_applicable
79 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 18, 2019
CompletedFirst Posted
Study publicly available on registry
September 20, 2019
CompletedStudy Start
First participant enrolled
December 11, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2031
March 31, 2026
March 1, 2026
8.1 years
September 18, 2019
March 27, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Composite endpoint including all-cause mortality, RVAD implantation or heart transplant, tricuspid valve intervention, heart failure hospitalizations, and Quality of Life improvement (measured by KCCQ score)
Comparison of number of participants with composite endpoint events between experimental and active comparator arms
12 months
Secondary Outcomes (14)
1 Grade Reduction in TR Severity
6, 12 months
Quality of Life (QOL) as Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)
3, 6, and 12 months
All Cause Mortality
12 months, 24 months
Death and Heart Failure Hospitalizations
12 months
All-cause Hospitalization
12 months
- +9 more secondary outcomes
Study Arms (4)
Edwards PASCAL System & OMT
EXPERIMENTALTranscatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation
Optimal Medical Therapy (OMT)
ACTIVE COMPARATOROptimal medical therapy (OMT) alone in patients with tricuspid regurgitation
Single-Arm Registry
EXPERIMENTALTranscatheter tricuspid valve repair with the Edwards PASCAL System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation who are not eligible for randomization
Continued Access Study
EXPERIMENTALTranscatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation
Interventions
Transcatheter tricuspid valve repair with the Edwards PASCAL System in patients on optimal medical therapy
Optimal Medical Therapy alone in patients with tricuspid regurgitation
Eligibility Criteria
You may qualify if:
- Eighteen (18) years of age or older
- Despite medical therapy, per the local Heart Team, patient has signs of TR, symptoms from TR, or prior heart failure hospitalization from TR.
- Severe or greater tricuspid regurgitation
- New York Heart Association (NYHA) Class II-IVa or heart failure hospitalization in the prior 12 months
- Patient is at an intermediate or greater estimated risk of mortality with tricuspid valve surgery as determined by the cardiac surgeon with concurrence by the local Heart Team
- Patient is able and willing to give informed consent, follow protocol procedures, and comply with follow-up visit requirements
You may not qualify if:
- Tricuspid valve anatomy not evaluable by TTE or TEE
- Tricuspid valve anatomy precludes proper device deployment and function
- Patient with refractory heart failure requiring, advanced intervention (i.e. patient has or will need left ventricular assist device, or transplantation) (ACC/AHA Stage D heart failure)
- Presence of trans-tricuspid pacemaker or defibrillator leads which meet one of the following:
- Would prevent proper TR reduction due to interaction of the lead with the leaflets
- Were implanted in the RV within the last 90 days prior to the point of enrollment
- Primary non-degenerative tricuspid disease
- Previous tricuspid valve repair or replacement that would interfere with placement of PASCAL
- Clinically significant, untreated coronary artery disease requiring revascularization, unstable angina, evidence of acute coronary syndrome, recent myocardial infarction
- Significant intra-cardiac mass, thrombus, or vegetation per echo core lab assessment
- Deep vein thrombosis (DVT) or pulmonary embolism (PE) in the last 90 days
- Recent Stroke
- Active gastrointestinal (GI) bleeding
- Presence of infiltrative cardiomyopathy or valvulopathy (including carcinoid, amyloidosis, sarcoidosis, hemochromatosis) or significant congenital heart disease, including but not limited to atrial septal defect, RV dysplasia, and arrhythmogenic RV
- Need for emergent or urgent surgery for any reason, any planned cardiac surgery within the next 12 months (365 days), or any planned percutaneous cardiac procedure within the next 90 days
- +15 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (79)
Banner University Medical Center Phoenix
Phoenix, Arizona, 85006, United States
Tucson Medical Center Healthcare
Tucson, Arizona, 85712, United States
University of California, Irvine
Irvine, California, 92868, United States
SCPMG - Kaiser San Diego
La Jolla, California, 92037, United States
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
UCLA Medical Center
Los Angeles, California, 90095, United States
Kaiser Permanente San Francisco
San Francisco, California, 94118, United States
University of California, San Francisco
San Francisco, California, 94143, United States
Stanford University
Stanford, California, 94305, United States
St. Joseph Hospital
Denver, Colorado, 80218, United States
Medical Center of the Rockies
Loveland, Colorado, 80538, United States
The Cardiac and Vascular Institute Research Foundation
Gainesville, Florida, 32605, United States
Mount Sinai Medical Center
Miami Beach, Florida, 33140, United States
NCH Healthcare System
Naples, Florida, 34102, United States
Sarasota Memorial Health Care System
Sarasota, Florida, 34239, United States
Tallahassee Research Institute
Tallahassee, Florida, 32308, United States
Emory University Hospital Midtown / Emory University - St. Joseph's Hospital
Atlanta, Georgia, 30308, United States
Piedmont Healthcare, Inc.
Atlanta, Georgia, 30309, United States
Northwestern University
Chicago, Illinois, 60611, United States
Ascension St. Vincent Heart Center Cardiovascular Research Institute
Indianapolis, Indiana, 46290, United States
University of Iowa Hospitals & Clinics
Iowa City, Iowa, 52242, United States
Ochsner Medical Center
New Orleans, Louisiana, 70121, United States
Johns Hopkins
Baltimore, Maryland, 21287, United States
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
University of Michigan
Ann Arbor, Michigan, 48109, United States
Henry Ford Hospital
Detroit, Michigan, 48202, United States
William Beaumont Hospital - Royal Oak
Royal Oak, Michigan, 48073, United States
St. Mary's of Ascension Research
Saginaw, Michigan, 48601, United States
Fairview Health Services
Maplewood, Minnesota, 55109, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, 64111, United States
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Providence St. Patrick Hospital
Missoula, Montana, 59802, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
Cooper Health Systems
Camden, New Jersey, 09103, United States
Morristown Medical Center
Morristown, New Jersey, 07962, United States
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey, 08901, United States
State University of New York at Buffalo
Buffalo, New York, 14203, United States
Columbia University Irving Medical Center/NYPH
New York, New York, 10032, United States
Weill Cornell Medicine
New York, New York, 10065, United States
Lenox Hill Hospital, Northwell Health /Northshore University Hospital Manhasset
New York, New York, 10075, United States
Rochester General Hospital
Rochester, New York, 14621, United States
St. Francis Hospital
Roslyn, New York, 11576, United States
Montefiore Medical Center / Arts Pavilion / Hutchinson Metro Center Clinic / Weiler Hospital / Moses Hospital
The Bronx, New York, 10467, United States
University of North Carolina
Chapel Hill, North Carolina, 27517, United States
Sanford Medical Center Fargo
Fargo, North Dakota, 58104, United States
The Christ Hospital
Cincinnati, Ohio, 45219, United States
TriHealth-Bethesda North Hospital
Cincinnati, Ohio, 45242, United States
The Ohio State University
Columbus, Ohio, 43210, United States
Integris Baptist Medical Center
Oklahoma City, Oklahoma, 73112, United States
Oklahoma Cardiovascular Research Group
Oklahoma City, Oklahoma, 73120, United States
Oklahoma Heart Institute at Hillcrest Medical Center
Tulsa, Oklahoma, 74104, United States
Oregon Health & Science University
Portland, Oregon, 97239, United States
Penn State Hershey
Hershey, Pennsylvania, 17033, United States
Pennsylvania Presbyterian Medical Center / Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Pinnacle Health Cardiovascular Institute/UPMC Pinnacle
Wormleysburg, Pennsylvania, 17043, United States
Lankenau Heart Institute
Wynnewood, Pennsylvania, 19096, United States
Medical University of South Carolina
Charleston, South Carolina, 29245, United States
Erlanger Health System
Chattanooga, Tennessee, 37403, United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37212, United States
HCA Houston Healthcare Medical Center
Houston, Texas, 77004, United States
Baylor College of Medicine St. Luke's Medical Center
Houston, Texas, 77030, United States
The University of Texas Health Science Center at Houston
Houston, Texas, 77030, United States
UTHealth/Memorial Hermann Hospital
Houston, Texas, 77030, United States
Baylor Scott & White - The Heart Hospital - Plano
Plano, Texas, 75093, United States
Intermountain Medical Center
Murray, Utah, 84107, United States
St. George Regional Hospital
St. George, Utah, 84790, United States
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
Virginia Commonwealth University
Richmond, Virginia, 23298, United States
Carilion Medical Center
Roanoke, Virginia, 24014, United States
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
Swedish Medical Center
Seattle, Washington, 98122, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
St. Paul's Hospital
Vancouver, British Columbia, V6Z 1Y6, Canada
Hamilton Health Services
Hamilton, Ontario, L8L 2X2, Canada
University of Ottawa Heart Institute
Ottawa, Ontario, K1Y 4Q7, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5, Canada
St. Michael's Hospital
Toronto, Ontario, M5B 1W8, Canada
Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval
Québec, Quebec, G1V 4G5, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Martin B. Leon, MD
Columbia University
- PRINCIPAL INVESTIGATOR
Michael J. Mack, MD
Baylor Scott and White Health
- PRINCIPAL INVESTIGATOR
Charles Davidson, MD
Northwestern University
- STUDY CHAIR
Allen Anderson, MD
The University of Texas Health Science Center at San Antonio
- STUDY CHAIR
Gorav Ailawadi, MD
University of Michigan
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 18, 2019
First Posted
September 20, 2019
Study Start
December 11, 2019
Primary Completion (Estimated)
December 31, 2027
Study Completion (Estimated)
December 31, 2031
Last Updated
March 31, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share